文献速递骨软组织肉瘤与黑色素瘤

BRAF、RAS和NF1三野生型黑色素瘤患者接受免疫检查点抑制剂的无进展生存期和总生存期缩短

Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.
PubMed 文献 · Eur J Cancer · 2024-07-06

本研究基于ADOREG/TRIM前瞻性多中心研究,对3109例黑色素瘤组织样本进行靶向测序,鉴定出292例三野生型(tWT)黑色素瘤患者。在141例IV期接受一线治疗的患者中,无论接受抗CTLA4联合抗PD1还是抗PD1单药,中位无进展生存期(mPFS)和中位总生存期(mOS)均较已知致癌基因突变黑色素瘤报告值显著缩短。

要点

  • 三野生型黑色素瘤占所有黑色素瘤的5-10%,TERT启动子突变见于33.2%的全部黑色素瘤。
  • 70.5%的三野生型黑色素瘤样本携带少于三个突变。
  • 一线抗CTLA4联合抗PD1的mPFS为6.2个月,mOS为24.8个月;抗PD1单药的mPFS为4个月,mOS为29.18个月。

核心结论

  • 在接受了抗CTLA4联合抗PD1或抗PD1单药一线治疗的IV期三野生型黑色素瘤患者中,两种方案均未观察到延长的mPFS或mOS。
  • 两种治疗方案的mPFS和mOS均较已知致癌基因突变黑色素瘤的报告值显著缩短。

研究设计与样本

  • 研究为前瞻性多中心研究ADOREG/TRIM(DeCOG),对3109例黑色素瘤组织样本进行TERT启动子和29个黑色素瘤相关基因的靶向下一代测序。
  • 共鉴定出292例三野生型黑色素瘤患者,其中141例AJCC IV期患者接受一线抗CTLA4联合抗PD1或抗PD1单药治疗作为亚组分析。

主要发现

  • 292例三野生型黑色素瘤患者包括184例皮肤黑色素瘤、56例黏膜黑色素瘤、34例肢端黑色素瘤和18例未知原发黑色素瘤(MUP)。
  • TERT启动子突变见于33.2%的全部黑色素瘤和70.5%的三野生型黑色素瘤样本携带少于三个突变。
  • 141例IV期患者中,一线抗CTLA4联合抗PD1治疗的mPFS为6.2个月(95%CI:4-9),mOS为24.8个月(95%CI:14.2-53.4)。
  • 一线抗PD1单药治疗的mPFS为4个月(95%CI:2.9-8.5),mOS为29.18个月(95%CI:17.5-46.2)。

关键数值与推荐

  • 三野生型黑色素瘤定义为缺乏BRAF、NRAS和NF1突变的黑色素瘤。
  • TERT启动子突变在全部黑色素瘤中占33.2%,在三野生型黑色素瘤中,70.5%的样本携带少于三个突变。

临床怎么用

  • 对于IV期三野生型黑色素瘤患者,一线抗CTLA4联合抗PD1或抗PD1单药治疗的mPFS和mOS均较已知致癌基因突变黑色素瘤的报告值缩短。
  • 已知预后因素如TERT启动子突变和TMB在两种治疗组间分布均衡,但两种方案均未显示延长的mPFS或mOS。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Melanomas lacking mutations in BRAF, NRAS and NF1 are frequently referred to as "triple wild-type" (tWT) melanomas. They constitute 5-10 % of all melanomas and remain poorly characterized regarding clinical characteristics and response to therapy. This study investigates the largest multicenter collection of tWT-melanomas to date. METHODS: Targeted next-generation sequencing of the TERT promoter and 29 melanoma-associated genes were performed on 3109 melanoma tissue samples of the prospective multicenter study ADOREG/TRIM of the DeCOG revealing 292 patients suffering from tWT-melanomas. Clinical characteristics and mutational patterns were analyzed. As subgroup analysis, we analyzed 141 tWT-melanoma patients receiving either anti-CTLA4 plus anti-PD1 or anti PD1 monotherapy as first line therapy in AJCC stage IV. RESULTS: 184 patients with cutaneous melanomas, 56 patients with mucosal melanomas, 34 patients with acral melanomas and 18 patients with melanomas of unknown origin (MUP) were included. A TERT promoter mutation could be identified in 33.2 % of all melanomas and 70.5 % of all tWT-melanomas harbored less than three mutations per sample. For the 141 patients with stage IV disease, mPFS independent of melanoma type was 6.2 months (95 % CI: 4-9) and mOS was 24.8 months (95 % CI: 14.2-53.4) after first line anti-CTLA4 plus anti-PD1 therapy. After first-line anti-PD1 monotherapy, mPFS was 4 months (95 %CI: 2.9-8.5) and mOS was 29.18 months (95 % CI: 17.5-46.2). CONCLUSIONS: While known prognostic factors such as TERT promoter mutations and TMB were equally distributed among patients who received either anti-CTLA4 plus anti-PD1 combination therapy or anti-PD1 monotherapy as first line therapy, we did not find a prolonged mPFS or mOS in either of those. For both therapy concepts, mPFS and mOS were considerably shorter than reported for melanomas with known oncogene mutations.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Jansen P, Galetzka W, Lodde GC, et al. Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas. Eur J Cancer. 2024. PMID: 39018633. doi:10.1016/j.ejca.2024.114208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。